FDA grants Imbruvica breakthrough therapy designation for cGVHD
AbbVie company Pharmacyclics and Janssen Biotech are jointly developing and commercializing Imbruvica, which is oral, once-daily therapy that inhibits Bruton’s tyrosine kinase (BTK) protein. The breakthrough therapy designation
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.